Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Zalcberg on Updated Results from the Phase 3 INVICTUS Study in Advanced GIST

September 20th 2020

John Zalcberg, PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.

Updated Data Demonstrate Continued PFS and OS Benefit With Ripretinib in Advanced GIST

September 19th 2020

The novel broad-spectrum KIT and PDGFRα inhibitor ripretinib continued to demonstrate clinically meaningful benefit as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumors.

More Frequent Dosing of Lanreotide Autogel Delays the Use of More Toxic Treatments in Pancreatic, Midgut NETs

September 19th 2020

Improvements in disease-free survival and progression-free survival were observed in patients with progressive pancreatic or midgut neuroendocrine tumors whose frequency of dosing for lanreotide Autogel was increased from 120 mg every 28 days to every 14 days.

Futibatinib Demonstrates Promising Responses in FGFR2+ Intrahepatic Cholangiocarcinoma

September 17th 2020

In an interim analysis of a subset of patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements, futibatinib was shown to be efficacious and tolerable.

Preclinical Data Suggest Novel Molecule Enhances Immunotherapy Response in CRC

September 17th 2020

Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.

Early Data Shows Neoadjuvant Nivolumab Potentializes Electroporation in HCC

September 16th 2020

Neoadjuvant nivolumab shrank tumors in 29% of patients with hepatocellular carcinoma at high risk for recurrence, which may kickstart the ablation effect of electroporation.

Dr. Ocean on the Development of Nanoliposomal Irinotecan in Metastatic Pancreatic Cancer

September 16th 2020

Allyson Ocean, MD, discusses the need for additional second-line therapies in metastatic pancreatic cancer.

Ramucirumab Maintains Activity, Tolerability After Non-Sorafenib Frontline Therapy in HCC

September 15th 2020

The safety and efficacy of ramucirumab administered after a frontline, non–sorafenib-based systemic therapy in hepatocellular carcinoma was consistent with data from the sorafenib-receiving intention-to-treat population of the phase 3 REACH-2 study.

CTLA-4/PD-L1 Blockade Boosts Response in HCC

September 15th 2020

The combination of tremelimumab and durvalumab improved overall response rate and median overall survival in patients with unresectable hepatocellular carcinoma previously treated with sorafenib.

Dr. Kim on the Safety Profile of Atezolizumab/Bevacizumab in HCC

September 14th 2020

Richard D. Kim, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

Cabozantinib Showcases Efficacy in Patients with HCC and Child-Pugh B

September 14th 2020

A retrospective analysis of data from the CELESTIAL trial has demonstrated the potential role for cabozantinib in patients with advanced hepatocellular carcinoma and Child-Pugh B liver cirrhosis.

Devimistat Moves Into Phase 3 Testing for Metastatic Pancreatic Cancer

September 11th 2020

AVENGER 500, a pivotal phase 3 clinical trial evaluating the efficacy and safety of devimistat for patients with metastatic pancreatic cancer, has achieved its target enrollment of 500 patients.

FDA Approves Copper Cu 64 Dotatate Injection for Somatostatin Receptor–Positive NETs

September 9th 2020

The FDA has approved copper Cu 64 dotatate injection for the localization of somatostatin receptor–positive neuroendocrine tumors.

Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric Cancer

September 8th 2020

Rutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.

Strosberg Shares Key Strategies Propelling Progress in Gastrointestinal Cancers

September 3rd 2020

Jonathan Strosberg, MD, highlights key trials spanning gastrointestinal cancers, challenges faced in certain diseases, and the focus of future research efforts.

Dr. Grothey on Left- Versus Right-Sided Tumors in CRC

September 2nd 2020

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Later-Line Treatment Approaches Make Headway in CRC Management

September 2nd 2020

Axel Grothey, MD, explains the impact of tumor sidedness on treatment decisions and highlights novel later-line approaches that are under examination in colorectal cancer.

Dr. VanderWalde on Utility of Radiation Therapy in Rectal Cancer

September 1st 2020

Noam VanderWalde, MD, MS, discusses radiation therapy in early-stage versus later-stage rectal cancer.

Dr. Grothey on Biomarkers to Inform Metastatic CRC Treatment Decisions

August 31st 2020

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Dr. Serrano on the Rationale for the INVICTUS Trial in Advanced GIST

August 28th 2020

César Serrano-García, MD, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.